Pre-treatment with anti-TGFβ1 was found to significantly reduce the rate of neurological decline in AOM-treated mice compared to AOM-treated IgG1 controls (p = 0.0268) with significant differences between the two groups at 17 h and 18 h after AOM injection (Fig. 2a). This evidence concerns the gene TGFB1 and infectious otitis media.